Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge

Vaccine

Volumn 28, Issue 1, 2009, Pages 79-89

  Barefoot, Brice E ^a   Athearn, Kathleen ^a   Sample, Christopher J ^a   Ramsburg, Elizabeth A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Influenza; Post exposure vaccine; rVSV

Indexed keywords

ALPHA INTERFERON; INFLUENZA HEMAGGLUTININ VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; FEMALE; GENE EXPRESSION SYSTEM; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFECTION PREVENTION; INFECTION RESISTANCE; INFLUENZA; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROVOCATION TEST; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS EXPRESSION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CRICETINAE; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; PLAQUE ASSAY; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL LOAD;

EID: 70649109920     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.112     Document Type: Article

References (44)

1. Massoudi M.S., Barker L., and Schwartz B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. J Infect Dis 188 7 (2003) 973-976
2. Rupprecht C.E., and Gibbons R.V. Clinical practice. Prophylaxis against rabies. N Engl J Med 351 25 (2004) 2626-2635
3. Yu A.S., Cheung R.C., and Keeffe E.B. Hepatitis B vaccines. Clin Liver Dis 8 2 (2004) 283-300
4. Ohmit S.E., Victor J.C., Teich E.R., Truscon R.K., Rotthoff J.R., Newton D.W., et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 198 3 (2008) 312-317
5. Clements M.L., and Murphy B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 23 1 (1986) 66-72
6. Yuen K.Y., Chan P.K., Peiris M., Tsang D.N., Que T.L., Shortridge K.F., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351 9101 (1998) 467-471
7. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 353 13 (2005) 1374-1385
8. Buxton Bridges C., Katz J.M., Seto W.H., Chan P.K., Tsang D., Ho W., et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 181 1 (2000) 344-348
9. Katz J.M., Lim W., Bridges C.B., Rowe T., Hu-Primmer J., Lu X., et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 180 6 (1999) 1763-1770
10. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 4 (2005) 333-340
11. Cohen J. Swine flu outbreak. Past pandemics provide mixed clues to H1N1's next moves. Science 324 5930 (2009) 996-997
12. Human infection with new influenza A (H1N1) virus: clinical observations from Mexico and other affected countries, May 2009. Wkly Epidemiol Rec 84 21 (2009) 185-189
13. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine-preliminary report. N Engl J Med (2009)
14. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of influenza A (H1N1) 2009 monovalent MF59-Adjuvanted vaccine-preliminary report. N Engl J Med (2009)
15. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 2 (2005) 174-182
16. Kahn J.S., Roberts A., Weibel C., Buonocore L., and Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75 22 (2001) 11079-11087
17. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 80 9 (2006) 4447-4457
18. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 8 (2004) 3930-3940
19. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 5 (2001) 539-549
20. Barefoot B.E., Sample C.J., and Ramsburg E.A. A vesicular stomatitis virus recombinant expressing influenza nucleoprotein induces CD8 T cell responses which enhance antibody mediated protection after lethal influenza challenge. Clin Vaccine Immunol (2009)
21. Daddario-DiCaprio K.M., Geisbert T.W., Geisbert J.B., Stroher U., Hensley L.E., Grolla A., et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 80 19 (2006) 9659-9666
22. Daddario-DiCaprio K.M., Geisbert T.W., Stroher U., Geisbert J.B., Grolla A., Fritz E.A., et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367 9520 (2006) 1399-1404
23. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Stroher U., Grolla A., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 3 1 (2007) e2
24. Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J., Geisbert J.B., Leung A., Feldmann F., et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82 11 (2008) 5664-5668
25. Lawson N.D., Stillman E.A., Whitt M.A., and Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92 10 (1995) 4477-4481
26. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., and Rose J.K. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol 76 6 (2002) 2730-2738
27. Suguitan Jr. A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3 9 (2006) e360
28. Schnell M.J., Buonocore L., Kretzschmar E., Johnson E., and Rose J.K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA 93 21 (1996) 11359-11365
29. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., Palin A., et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol 79 24 (2005) 15043-15053
30. Publicover J., Ramsburg E., Robek M., and Rose J.K. Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha. J Virol 80 14 (2006) 7028-7036
31. Toth L.A., Rehg J.E., and Webster R.G. Strain differences in sleep and other pathophysiological sequelae of influenza virus infection in naive and immunized mice. J Neuroimmunol 58 1 (1995) 89-99
32. Beilharz M.W., Cummins J.M., and Bennett A.L. Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem Biophys Res Commun 355 3 (2007) 740-744
33. Isomura S., Ichikawa T., Miyazu M., Naruse H., Shibata M., Imanishi J., et al. The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken J 25 3 (1982) 131-137
34. Van Hoeven N., Belser J.A., Szretter K.J., Zeng H., Staeheli P., Swayne D.E., et al. Pathogenesis of the 1918 pandemic and H5N1 influenza virus infection in a guinea pig model: the antiviral potential of exogenous alpha-interferon to reduce virus shedding. J Virol (2009)
35. Staeheli P., Grob R., Meier E., Sutcliffe J.G., and Haller O. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol 8 10 (1988) 4518-4523
36. Staeheli P., Haller O., Boll W., Lindenmann J., and Weissmann C. Mx protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 44 1 (1986) 147-158
37. Durbin J.E., Fernandez-Sesma A., Lee C.K., Rao T.D., Frey A.B., Moran T.M., et al. Type I IFN modulates innate and specific antiviral immunity. J Immunol 164 8 (2000) 4220-4228
38. Lawrence C.W., and Braciale T.J. Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 173 2 (2004) 1209-1218
39. Lawrence C.W., Ream R.M., and Braciale T.J. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 174 9 (2005) 5332-5340
40. Topham D.J., Tripp R.A., and Doherty P.C. CD8+T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159 11 (1997) 5197-5200
41. Pavlovic J., Haller O., and Staeheli P. Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. J Virol 66 4 (1992) 2564-2569
42. Garcia-Sastre A., Durbin R.K., Zheng H., Palese P., Gertner R., Levy D.E., et al. The role of interferon in influenza virus tissue tropism. J Virol 72 11 (1998) 8550-8558
43. Fink K., Lang K.S., Manjarrez-Orduno N., Junt T., Senn B.M., Holdener M., et al. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur J Immunol 36 8 (2006) 2094-2105
44. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferons in antiviral defense. Science 264 5167 (1994) 1918-1921